Aeromonas spp. Human Infection: Retrospective Study in the region of Sousse, 2011 – 2015

##plugins.themes.academic_pro.article.sidebar##

Published Dec 15, 2017
Download
pdf
Vol. 95 No. 4 (2017): Issue Apr 2017

##plugins.themes.academic_pro.article.main##

Hichem Bargui
Manel Marzouk
Ahmed Benhadj
Moufida Hadj Ali
Youssef Ben Salem
Jalel Boukadida

Abstract

Objective: To present the clinical and bacteriological characteristics of human Aeromonas infections in the central region of Tunisia from January 2011 to September 2015.
Methods: Retrospective study concerning all Aeromonas spp strains isolated at our laboratory during a period of 5 years (2011-2015). Following data were collected: gender, age, hospital department, co-morbidities, site of infection, date, the Aeromonas species and susceptibility phenotype. Identification was based on conventional criteria and antibiotic susceptibility was performed according to the recommendations of “the Committee of the French Society of Microbiology»
Results: Thirty six strains of Aeromonas spp were collected during our study period. Mean age was 24 years old with a sex ratio of 1.1. The samples mainly provided from internal medicine (30,5%), neonatology (19,4%). Digestive tract (33%), blood stream (33%), skin and soft tissues (17%) and urinary tract (3%) were the sites of infection. Five infections (14%) were nosocomial, associated with biomaterials. The quart of patients was immuno-compromised. The seasonal distribution showed a summer-autumn peak. We noted 2 species: A. hydrophila (83%) and A. veronii biovar sobria (17%). All strains were resistant to amoxicillin and amoxicillin-clavulanic acid whereas we noted effectiveness of third-generation cephalosporins (C3G), fluoroquinolones and aminoglycosids.All patients received antibiotic treatment: 93% an association. Four deaths occured not directly linked to Aeromonas infection.
Conclusion: In our area, Aeromonas infections must be mentioned in case of diarrhea, especially during summer-autumn or sepsis particularly in immunocompromised patients.  A. hydrophila remains the most frequent species at our patients. Due to their resistance to aminopenicillins, a probabilistic treatment including either a fluoroquinolone or a C3G, evently associated with an aminoglycoside, should be conducted.

Keywords:

Aeromonas spp, human infections, characteristics, Tunisia

##plugins.themes.academic_pro.article.details##

References

  1. Harf-Monteil C et Monteil H. Aeromonas. In: Freney J, Renaud F, Leclercq R et Riegel P, éd. Bactériologie Clinique. Paris: ESKA 2007. P 1167-75.
  2. Janda JM, Abbott SL. The genus Aeromonas: taxonomy, pathogenicity, and infectious. Clin Microbiol Rev 2010; 23:35-73.
  3. von Graevenitz A. the role of Aeromonas in diarrhea: a review. Infection 2007; 35:59-64.
  4. Horneman AJ and Afsar A. Aeromonas. In : Versalovic J, Carroll KC, Funke G, Jorgensen JH, Landry ML, Warnock DW, éd. Manual of clinical microbiology. Washington DC 2011 10th edition. P 658-65.
  5. Fraisse T, Lechiche C, Sotto A, Lavigne JP. Infections à Aeromonas spp : étude rétrospective de 1997 à 2004 au CHU de Nîmes. Pathol Biol 2008; 56: 70-6.
  6. Janda JM, Guthertz LS, Kokka RP, Shimada T. Aeromonas species in septicemia: laboratory characteristics and clinical observations. Clin Infect Dis 1994;19:77-83.
  7. Ko WC, Chuang YC. Aeromonas bacteremia: review of 59 episodes. Clin Infect Dis 1995;20:1298-304.
  8. Duthie R, Ling TW, Cheng AFB, French GL. Aeromonas septicemia in Hong Kong species distribution and associated disease. J Infect 1995; 30:241-4.
  9. Ko WC, Lee HC, Chuang YC, et al. Clinical features and therapeutic implications of 104 episodes of monomicrobial Aeromonas bacteremia. J Infect 2000; 40:267-73.
  10. Tsai MS, Kuo CY, Wang MC, et al. Clinical features and risk factors for mortality in Aeromonas bacteriemic adults with hematologic malignancies. J Microbiol Immunol Infect 2006; 39:150-4.
  11. Burke V, Robinson J, Gracey M, et al. Isolation of Aeromonas hydrophila from a metropolitan water supply: seasonnal correlation with clinical isolates. Appl Environ Microbiol 1984;48:361-6.
  12. Wu CJ, Wu JJ, Yan JJ, et al. Clinical significance and distribution of putative virulence markers of 116 consecutive clinical Aeromonas isolates in southern Taiwan. J Infect 2007;54:151-8.
  13. Cattoir V, Poirel L, Aubert C, et al. Unexpected occurrence of plasmid-mediated quinolone resistance determinants in environmental Aeromonas spp. Emerg Infect Dis. 2008; 14:231-7.
  14. Goni-Urriza M, Arpin C, Capdepuy M, et al. Type II topoisomerase quinolone resistance determining regions of Aeromonas caviae, A. hydrophila, and A. sobria complexes and mutations associated with quinolone resistance. Antimicrob Agents Chemother 2002; 46:350-9.
  15. Ko WC, Lee HC, Chuang YC, et al. In vitro and in vivo combination of cefotaxime and minocycline against Aeromonas hydrophila. Antimicrob Agents Chemother 2001; 45:1281-3.
  16. Chamorey E, Forel M, Drancourt M. An in vitro evaluation of the activity of chlorine against environnemental and nosocomial isolates of Aeromonas hydrophila. J. Hosp. Infect 1999; 41:45-9.